Boehringer marks survodutide cardiovascular outcomes trial SYNCHRONIZE-CVOT as completed
The event-driven Phase 3 study randomized adults with BMI of 27 or more to two survodutide doses or placebo for up to two years and three months.
PR
By Priya Raman · Science Reporter
Sep 30 08:00 ETSource: ClinicalTrials.gov
The wire
- 01ClinicalTrials.gov lists NCT06077864, Boehringer Ingelheim's Phase 3 cardiovascular safety trial of once-weekly subcutaneous survodutide, as completed; it started 20 November 2023.
- 02Participants had established cardiovascular or chronic kidney disease, or at least two weight-related complications or risk factors, making this the safety dataset regulators will weigh for the GLP-1/glucagon dual agonist.
- 03The registry entry gives status only; primary cardiovascular event results and blood pressure outcomes have not been reported in this listing.
From the source
Read at clinicaltrials.govA Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864 · PHASE3 · COMPLETED · Sponsor: Boehringer Ingelheim · Conditions: Obesity.
Source URL https://clinicaltrials.gov/study/NCT06077864
